Home›Trial›NCT03992755
🔬NCT03992755Phase 3ACTIVE NOT RECRUITING

Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil

Study Summary

The primary objective of this study is to evaluate the long-term safety of LIQ861 in patients with pulmonary arterial hypertension (PAH).

Conditions
Primary Pulmonary Hypertension
Interventions / Drugs
LIQ861 Inhaled Treprostinil
View on ClinicalTrials.gov ↗
Sponsor
LQDA
Liquidia Technologies
Pulmonary
D36/100
Study Details
Enrollment92 participants
Primary Completion—
Lead SponsorLiquidia Technologies, Inc.
Data Retrieved2026-04-11 04:20:00.960800+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.